At a glance
ClinicalIndex Comparison Record- ✓Diagnosis of mediastinal gray zone lymphoma or primary mediastinal B-cell lymphoma, confirmed by NCI Hematopathology Section
- ✓Age ≥12 years old
- ✓Any stage disease
- ✓No prior systemic chemotherapy (prior limited-field radiotherapy, short course glucocorticoids, and/or cyclophosphamide for urgent problems at diagnosis permitted)
- ✕Other serious concomitant medical illnesses or uncontrolled active infection that would jeopardize ability to receive the regimen with reasonable safety
- ✕History of unrelated neoplasms within past 5 years, except non-melanoma skin cancer or in-situ cancer
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Dose-Adjusted EPOCH Chemotherapy and Rituximab (CD20+) in Adults and Children With Previously Untreated Patients With Aggressive Non-Hodgkin's Lymphoma
In Brief
A Phase 2 clinical trial evaluating Etoposide, Rituximab, and 14 other interventions for Diffuse Large B-Cell Lymphoma (DLBCL) and 4 related conditions. Completed, enrolled 348 participants across 5 sites.
Detailed Summary
5-Drug Combination Chemotherapy with Hematologic Toxicity Attenuation. Etoposide phosphate, prednisone, vincristine sulfate (Oncovin), cyclophosphamide, and doxorubicin hydrochloride (hydroxydaunorubicin)(EPOCH): Etoposide, VP-16, NSC-141540; Prednisone, PRED, NSC-10023; Vincristine, VCR, NSC-67574; Cyclophosphamide, CTX, NSC-26271; Doxorubicin, DOX, NSC-123127; with Granulocyte Colony-Stimulating Factor (Amgen), Granulocyte colony-stimulating factor (G-CSF), NSC-614629.
Study Details
Timeline
Interventions
Etoposide 50mg/m\^2/day were delivered as continuous intravenous (CIV) infusions over 96 hours starting on day 1 every 21 days. Combination chemotherapy given with Rituximab, Etoposide, VP-16; Prednisone, Cyclophosphamide, Vincristine, and Doxorubicin (EPOCH-R) intravenous (IV) every 3 weeks for 6 cycles.
Rituximab given on Day 1 of combination chemotherapy (EPOCH-R) every 3 weeks for 6 cycles. Combination chemotherapy given with Rituximab, Etoposide, VP-16; Prednisone, Cyclophosphamide, Vincristine, and Doxorubicin (EPOCH-R) intravenous (IV) every 3 weeks for 6 cycles.
Prednisone 100mg by mouth (PO) twice a day (bid) on days 1 through 5 every 21 days. Combination chemotherapy given with Rituximab, Etoposide, VP-16; Prednisone, Cyclophosphamide, Vincristine, and Doxorubicin (EPOCH-R) intravenous (IV) every 3 weeks for 6 cycles.
Cyclophosphamide 750mg/m\^2 on day 5 every 21 days. Combination chemotherapy given with Rituximab, Etoposide, VP-16; Prednisone, Cyclophosphamide, Vincristine, and Doxorubicin (EPOCH-R) intravenous (IV) every 3 weeks for 6 cycles.
Vincristine 0.4mg/m\^2/day. Combination chemotherapy given with Rituximab, Etoposide, VP-16; Prednisone, Cyclophosphamide, Vincristine, and Doxorubicin (EPOCH-R) intravenous (IV) every 3 weeks for 6 cycles.
Doxorubicin 10mg/m\^2/day. Combination chemotherapy given with Rituximab, Etoposide, VP-16; Prednisone, Cyclophosphamide, Vincristine, and Doxorubicin (EPOCH-R) intravenous (IV) every 3 weeks for 6 cycles.
Baseline and/or on completion of therapy.
Baseline and/or on completion of therapy.
Baseline and/or on completion of therapy.
As clinically indicated.
As clinically indicated.
Nausea and/or vomiting.
Nausea and/or vomiting.
Gastroesophageal reflux disease (GERD).
Constipation.
Constipation